All AbMole products are for research use only, cannot be used for human consumption.
Ecromeximab-MMAE is an antibody-drug conjugate (ADC) targeting ganglioside GD3.
Subtype IgG1
Molecular weight 150 kDa
Endotoxin <1 EU/mg
| Solubility (25°C) | For lyophilized powder, reconstitute with distilled water to a final concentration of 1 mg/ml. Do not vortex. |
| Storage | Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles. |
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Ensituximab-MMAE
Ensituximab-MMAE is an antibody-drug conjugate (ADC) targeting a variant of MUC5AC. |
| Inotuzumab MMAE
Inotuzumab MMAE is an anti-CD22 antibody-drug conjugate (ADC). |
| Ulocuplumab-MMAE
Ulocuplumab-MMAE is an antibody-drug conjugate (ADC). |
| Lorvotuzumab-MMAE
Lorvotuzumab-MMAE is an antibody-drug conjugate (ADC). |
| Anetumab-MMAE
Anetumab-MMAE is an antibody-drug conjugate (ADC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
